Patent ID: 11919964
Assignee: AMGEN INC.
Field: Biotechnology (Chemistry)
Classification: CPC C  A | IPC C

Claim 23:
24. The bispecific heterodimeric antibody of claim 1, wherein LC1 comprises a light chain variable region (VL1) comprising a CDRL1, CDRL2, and CDRL3 and HC1 comprises a heavy chain variable region (VH1) comprising a CDRH1, CDRH2, and CDRH3, and wherein:
(a) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 109, 120 and 127, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 159, 167 and 179, respectively;
(b) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 109, 120 and 127, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 159, 168 and 179, respectively;
(c) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 110, 121 and 128, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 160, 169 and 180, respectively;
(d) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 110, 121 and 128, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 160, 169 and 181, respectively;
(e) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 111, 17 and 129, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 161, 170 and 182, respectively; or
(f) CDRL1, CDRL2, and CDRL3 have the sequence of SEQ ID NOs: 111, 17 and 129, respectively, and CDRH1, CDRH2, and CDRH3 have the sequence of SEQ ID NOs: 161, 171 and 182, respectively.